PEPTIDESGRID
Prices read Nov 19, 2026

Which of these peptides are FDA approved, or approved elsewhere?

Updated Sep 27, 2026, first published Sep 25, 2026

Research peptide stores sell these compounds as research chemicals, not as medicines. Some of the same ingredients are in approved medicines, but an approval covers one maker's finished product. The listings on PeptidesGrid are sold as research chemicals, not as the approved products named below.

This page gives the regulatory status of all 54 peptides on the site, checked Sep 25 and 26, 2026. It is a status check only. It is not medical advice and not advice to use anything.

How we checked

On Sep 25, 2026 we searched Drugs@FDA, the European Medicines Agency (EMA) medicines list and Health Canada's Drug Product Database for every ingredient. For products still in trials we read the companies' own releases. For approvals in other countries we checked company filings and Vidal, a Russian drug reference that lists each product's registration, with its Belarus edition. We also checked France's ANSM medicines database, Japan's PMDA, Italy's AIFA medicines database, India's CDSCO list of new drugs and EMA lists of nationally authorised products. We did not search every country's register. We checked the eight peptides added on Sep 26, 2026 (Thymalin, Gonadorelin, Adipotide, Testagen, Cartalax, Cardiogen, PNC-27 and Prostamax) on that day.

Status of all 54 peptides

Regulatory status of the 54 peptides, checked Sep 25 and 26, 2026, grouped by status
PeptideStatus, checked Sep 25 or 26, 2026
Approved in the US, EU or Canada
TirzepatideMounjaro and Zepbound, from Eli Lilly. Approved by the FDA (Mounjaro, 2022; Zepbound, 2023), the EMA (Mounjaro, 2022) and Health Canada (Mounjaro, Zepbound).
SemaglutideOzempic, Wegovy and Rybelsus, from Novo Nordisk. Approved by the FDA, the EMA and Health Canada. The EMA also approved Kayshild (Novo Nordisk) in March 2026. Health Canada approved generic semaglutide from Dr. Reddy's (announced April 28, 2026), then from Apotex (including Sevmia), Aspen and Sandoz.
TesamorelinEgrifta, from Theratechnologies. FDA, 2010. The EU application was withdrawn in 2012. Health Canada's listings were cancelled in 2022 and 2023.
SS-31Elamipretide, sold as Forzinity by Stealth BioTherapeutics, now Mighty Therapeutics. FDA accelerated approval (an approval based on early evidence, which the company must confirm in later studies), September 19, 2025. Not approved in the EU or Canada.
PT-141Bremelanotide, sold as Vyleesi by Cosette Pharmaceuticals. FDA, 2019. Not approved in the EU or Canada.
OxytocinPitocin, from Par Health, is FDA approved. Other makers' oxytocin injections are approved in the US and Canada.
Melanotan IAfamelanotide, sold as a 16 mg implant (Scenesse) by Clinuvel. Approved by the EMA (2014), the FDA (2019) and Health Canada (2026). Research vendors sell the peptide in vials, which is not the approved product.
Approved for people elsewhere, not currently by the FDA, EMA or Health Canada
MazdutideXinermei, from Innovent Biologics under a license from Eli Lilly. China's NMPA approved it on June 27, 2025, with a second approval on September 19, 2025.
Thymosin Alpha-1Thymalfasin, sold as Zadaxin by SciClone Pharmaceuticals. SciClone's annual report for 2004 lists approvals in over 30 countries, mainly in Asia, the Middle East and Latin America.
SelankSelank, from Peptogen, is registered as a medicine in Russia.
SemaxSemax, from Peptogen, is registered as a medicine in Russia. An FDA advisory committee voted on compounding it in July 2026. That is not an approval; see below.
DSIPDeltaran, from the KOMKON research center, contains DSIP. It is registered in Russia (registration LP-003849). An FDA advisory committee voted against compounding it, as emideltide, in July 2026; see below.
GHRP-2Pralmorelin, sold in Japan as GHRP Kaken 100 (Kaken Pharmaceutical) for diagnosing growth hormone deficiency. Approved in Japan in 2004.
VIPAviptadil, combined with phentolamine as Invicorp (Evolan Pharma), is authorised nationally in Germany, Denmark, Finland, France, Norway, Sweden and Northern Ireland, according to an EMA list from October 2022. Sweden still lists it. In April 2022 India's regulator gave a single-ingredient aviptadil injection a restricted emergency approval. Not approved by the FDA, the EMA or Health Canada.
GlutathioneGlutathione injections are approved medicines in Japan (Tathion, from Choseido Pharmaceutical) and Italy (TAD, from Biomedica Foscama, and others). Not approved by the FDA, the EMA or Health Canada. Its oxidised form is a minor ingredient of approved eye irrigation solutions such as BSS Plus.
ThymalinThymalin, an extract of cattle thymus, is registered as a prescription medicine in Russia (Samson-Med) and Belarus (Belmedpreparaty). It is an extract, not one defined peptide, so vials research vendors sell under the name are not that product. Not approved by the FDA, the EMA or Health Canada.
GonadorelinAuthorised for people in France as Lutrelef and LHRH Ferring (Ferring), per the ANSM database (Lutrelef, LHRH Ferring). The FDA approved it for people as Factrel (1982) and Lutrepulse (1989), both since discontinued. The only gonadorelin products the FDA lists for use today are injections for cattle. No EMA authorisation.
In clinical development
RetatrutideEli Lilly, phase 3 (the large trials run before a company applies for approval). On July 23, 2026 Lilly said it planned to apply for US approval in Q1 2027.
CagrilintideNovo Nordisk, phase 3. On September 16, 2025 Novo said it would move it into its own phase 3 program, RENEW.
CagriSemaNovo Nordisk applied for FDA approval on December 18, 2025. Its Q2 2026 report (August 4, 2026) expected the US decision in Q4 2026.
SurvodutidePhase 3, run by Boehringer Ingelheim, which licensed it from Zealand Pharma. On August 13, 2026 Zealand Pharma said results from SYNCHRONIZE-2 would be presented at the EASD meeting, September 28 to October 2, 2026.
Not currently approved anywhere we could find
BPC-157, TB-500, KPV, MOTS-c, EpitalonNo approved product found. An FDA advisory committee voted on compounding them in July 2026. That is not an approval; see below.
GHK-Cu, Ipamorelin, CJC-1295 no DAC, CJC-1295 DAC, HGH Frag 176-191, AOD-9604, Kisspeptin-10No approved product found.
NAD+Not a peptide. No approved NAD+ product found.
Melanotan IINo approved product found. A different peptide, afamelanotide (melanotan I), is approved as Scenesse (Clinuvel) in the EU, the US and Canada.
SermorelinOnce approved in the US as Geref (EMD Serono). The maker stopped selling it, and the FDA withdrew the approvals in 2009.
BPC-157 + TB-500, GLOW, KLOW, CJC-1295 + IpamorelinVendor blends. No approved product contains these mixes.
LL-37, ARA-290, Pinealon, FOXO4-DRI, GHRP-6, HexarelinNo approved product found.
IGF-1 LR3No approved product found. Mecasermin (Increlex), which is unmodified IGF-1, is approved by the FDA (2005), the EMA (2007) and Health Canada; it is a different molecule.
SNAP-8Acetyl octapeptide-3, listed as a cosmetic ingredient in the EU. Not approved as a medicine.
Adipotide, PNC-27, Testagen, Cartalax, ProstamaxNo approved product found.
CardiogenNo approved product found. CardioGen-82, an FDA-approved rubidium Rb 82 generator from Bracco used in heart imaging, is an unrelated product with a similar name.

What "approved" means here

Re-check dates:

Status checked Sep 25 and 26, 2026 against Drugs@FDA, the EMA medicines list, Health Canada's Drug Product Database, Vidal (Russia and Belarus), France's ANSM database, PMDA, AIFA, CDSCO and company releases. Approvals change, so check the regulator's own record. Last reviewed Sep 27, 2026.

More buyer guides